Urigen Pharmaceuticals, Inc. Provides Corporate Update on Partnering Activities and Pursuit of Strategic Alternatives

SAN FRANCISCO--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc. (OTC BB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that it is pursuing strategic alternatives to maximize the value from its two proprietary platform technologies. The Company is currently in discussions with various pharmaceutical companies to license or engage in a joint venture for its two lead platforms, URG 101 and URG 301. URG101 is a proprietary combination of approved drugs that is instilled into the bladder, targeting painful bladder syndrome, which affects approximately 10.5 million men and women in North America. URG301 is the Company’s proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major un-met need that is insufficiently managed by presently available overactive bladder drugs. The Company is also considering mergers, acquisitions or investments from strategic partners.